Patient level factors associated with chronic opioid use in cancer patients.

Authors

null

Colleen Ann Cuthbert

University of Calgary, Calgary, AB, Canada

Colleen Ann Cuthbert , Yuan Xu , Devon J. Boyne , Shiying Kong , Brenda R. Hemmelgarn , Winson Y. Cheung

Organizations

University of Calgary, Calgary, AB, Canada, Alberta Health Services, Calgary, AB, Canada

Research Funding

Other

Background: Opioid prescribing in oncology is increasingly scrutinized given public health concerns about chronic opioid use, misuse, and harms. We aimed to evaluate patient reported pain scores, mental health indicators, prior opioid use, and number of opioid prescribers as potential risk factors for chronic opioid use in a large Canadian province. Methods: This was a population-based cohort study using administrative health data of patients in Alberta, Canada, diagnosed between Jan 2016 and Jan 2017, and completed a prospective comprehensive symptom survey within +/- 60 days of diagnosis. Patients were divided into two groups: chronic opioid use (COU) (defined as continuous prescriptions for opioids for at least 90 days post diagnosis) and non-chronic opioid use (NCOU). Logistic regression models were used to evaluate factors associated with COU. Results: We included 694 patients. Most had breast (20%), colorectal (13%), and lung (33%) cancers. There were no differences in mean age (65 years) or gender (50% female) between the groups. In total, 32% had moderate to high pain scores at diagnosis. Of the 14% with COU, 79% were opioid naïve at diagnosis. Those in the COU group were more often diagnosed with advanced stage of disease (66% vs 40%), had lung cancer (47%), and were opioid tolerant at diagnosis (defined as > 90 days of continuous opioids within 1 year prior to their diagnosis) (21% vs 3%). In comparison, 64% of COU versus 27% of NCOU had moderate to severe pain scores at diagnosis (p < 0.001). COU had significantly higher anxiety and depression scores at diagnosis versus NCOU (p = 0.004). Among patients with COU, morphine equivalent daily doses increased from 27.3 (pre-diagnosis) to 65.1 (post-diagnosis). Irrespective of treatment type or stage, those who had moderate to high pain scores, were opioid tolerant at diagnosis, or had multiple prescribers were at greater risk for COU (see Table). Conclusions: Specific patient groups were at increased risk of COU and should be the focus of adaptive prescribing approaches to ensure that opioid use is appropriate.

VariableAdjusted OR (95%CI)P value
Pain score
Mild painreferent
Moderate pain1.7 (1.1-3.6)0.03
Severe pain2.6 (1.1-6.1)0.03
Opioid use pre-diagnosis
Naivereferent
Tolerant3.3 (1.3-8.5)0.01
Number of prescribers (continuous)2.3 (1.8-2.9)< .001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11580)

DOI

10.1200/JCO.2019.37.15_suppl.11580

Abstract #

11580

Poster Bd #

272

Abstract Disclosures

Similar Abstracts

Abstract

2021 ASCO Annual Meeting

Analysis of opioid and adjunctive pain medication prescriptions in lung cancer patients.

First Author: Benjamin Aaron Bleiberg

First Author: Christopher John Coyne

Abstract

2023 ASCO Quality Care Symposium

The role of primary care in opioid prescribing for head and neck cancer (HNC) survivors.

First Author: Talya Salz